Biosimilars Serving the twin purposes of creating a globally competitive biopharmaceutical industry that addresses India's major concerns around barriers to affordable healthcare, India's Department of Biotechnology (DBT) is set to roll out biosimilar drugs for diseases such as cancer, diabetes and rheumatoid arthritis, reports The Pharma Letter’s India correspondent. 11 July 2017